A decision tree cost-utility analysis found ICG more cost-effective than methylene blue for SLNB in breast cancer (ICER $4,044/QALY), with Monte Carlo simulation showing an 80% probability of ICG superiority.
Sonia H. Lee
Advertisement
Articles by Sonia H. Lee
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
31 E-Strain Elastography as an Adjunct of Breast Ultrasound: Impact on Biopsy Decision-Making
2
ASCO Breakthrough 2026 Wrap-Up: Precision Oncology, AI, and Biomarkers Define the Future of Cancer Care
3
Epcoritamab/Lenalidomide Significantly Improves PFS in R/R DLBCL
4
FDA Accepts RP1 BLA Resubmission for Advanced Melanoma
5